Akèy › Lukemi lenfositè kwonik › Tennessee
Etid klinik pou Lukemi lenfositè kwonik nan Tennessee
17 etid pou Lukemi lenfositè kwonik ap chèche patisipan nan sit nan Tennessee.
Vil nan Tennessee
Tèks ofisyèl etid la (Anglè)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
Ap rekriteFaz 3
Laj 65 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07321652Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Ballad Health Cancer Care - Kingsport, Kingsport
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT04269902A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Tennessee Oncology Greco Hainsworth Centers For Research Chattanooga, Chattanooga
- Tennessee Oncology, Nashville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06943872A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Tennesse Oncology Chattanooga Downtown, Chattanooga
- Tennessee Oncology, Pllc Nashville, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05006716A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Tennessee Oncology, Pllc Nashville, Nashville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06973187A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Tennessee Oncology-Chattanooga ( Site 0045), Chattanooga
- Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 0031), Nashville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06136559A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- SCRI Oncology Partners, Nashville
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07221500Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
- SCRI Oncology Partners, Nashville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 31, 2026 · NCT07516093Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- SCRI Oncology Partners, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07520006A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Sarah Cannon Research Institute SCRI, Nashville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05254743Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- TriStar BMT, Nashville
Ap rekriteFaz 1/2
Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- The West Clinic, PLLC dba West Cancer Center, Germantown
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 19, 2026 · NCT06588478The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Baptist Clinical Research Institute, Memphis
Ap rekriteFaz 1/2
Laj 12 a 95 · Tout sèks · Mizajou Apr 15, 2026 · NCT04329728A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Tennessee Oncology, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Mar 20, 2026 · NCT04830137A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Tennessee Oncology, Nashville
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Mar 2, 2026 · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Tennessee Oncology, Nashville
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Mar 2, 2026 · NCT06876649HPC Offered for PRESERVE Expansion
- Tristar Centennial Medical Center, Nashville
Ap rekriteEtid obsèvasyon
Laj 12 a 80 · Tout sèks · Mizajou Aug 28, 2025 · NCT07145411Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.